NRx Pharmaceuticals (NASDAQ:NRXP) Receives Buy Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a report issued on Tuesday,Benzinga reports. D. Boral Capital currently has a $34.00 price objective on the stock.

Other equities research analysts also recently issued research reports about the company. BTIG Research reissued a “buy” rating and set a $25.00 price target on shares of NRx Pharmaceuticals in a research report on Thursday, January 15th. Ascendiant Capital Markets reissued a “buy” rating and set a $48.00 target price (up from $47.00) on shares of NRx Pharmaceuticals in a report on Friday, January 2nd. Zacks Research cut NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, January 26th. Wall Street Zen raised shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, November 23rd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research note on Monday, December 29th. Four analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, NRx Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $36.75.

NRx Pharmaceuticals Price Performance

NASDAQ NRXP opened at $1.80 on Tuesday. The firm has a 50-day moving average price of $2.20 and a two-hundred day moving average price of $2.56. NRx Pharmaceuticals has a 12-month low of $1.58 and a 12-month high of $3.84. The company has a market capitalization of $53.28 million, a P/E ratio of -0.77 and a beta of 1.91.

Hedge Funds Weigh In On NRx Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in NRXP. Ethos Financial Group LLC acquired a new stake in NRx Pharmaceuticals in the third quarter valued at approximately $39,000. Sjbenen Advisory LLC bought a new position in shares of NRx Pharmaceuticals in the 4th quarter valued at $41,000. One Wealth Management Investment & Advisory Services LLC boosted its holdings in shares of NRx Pharmaceuticals by 86.1% during the 3rd quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock valued at $92,000 after acquiring an additional 12,950 shares in the last quarter. Global Retirement Partners LLC bought a new stake in NRx Pharmaceuticals during the 4th quarter worth $107,000. Finally, Two Sigma Investments LP increased its holdings in NRx Pharmaceuticals by 66.4% in the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after purchasing an additional 20,880 shares in the last quarter. Institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.